These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3783047)

  • 1. Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects.
    Packard CJ; Clegg RJ; Dominiczak MH; Lorimer AR; Shepherd J
    J Lipid Res; 1986 Sep; 27(9):930-8. PubMed ID: 3783047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
    Winocour PH; Durrington PN; Bhatagnar D; Ishola M; Mackness M; Arrol S; Anderson DC
    Atherosclerosis; 1992 Mar; 93(1-2):83-94. PubMed ID: 1596307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma apolipoprotein B metabolism in familial type III dysbetalipoproteinaemia.
    Turner PR; Cortese C; Wootton R; Marenah C; Miller NE; Lewis B
    Eur J Clin Invest; 1985 Apr; 15(2):100-12. PubMed ID: 3922766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.
    Taskinen MR; Packard CJ; Shepherd J
    Diabetes; 1990 Sep; 39(9):1017-27. PubMed ID: 2200727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects.
    Packard CJ; Munro A; Lorimer AR; Gotto AM; Shepherd J
    J Clin Invest; 1984 Dec; 74(6):2178-92. PubMed ID: 6511922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.
    Shepherd J; Packard CJ; Stewart JM; Atmeh RF; Clark RS; Boag DE; Carr K; Lorimer AR; Ballantyne D; Morgan HG
    J Clin Invest; 1984 Dec; 74(6):2164-77. PubMed ID: 6511921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
    Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
    J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The independent synthesis of intermediate density lipoproteins in type III hyperlipoproteinemia.
    Reardon MF; Poapst ME; Steiner G
    Metabolism; 1982 May; 31(5):421-7. PubMed ID: 7078425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D; Oschry Y; Fainaru M; Eisenberg S
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolism of apolipoprotein B in subjects with hypertriglyceridemia and polydisperse LDL.
    Fisher WR; Zech LA; Bardalaye P; Warmke G; Berman M
    J Lipid Res; 1980 Aug; 21(6):760-74. PubMed ID: 7419987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins.
    Bradley WA; Hwang SL; Karlin JB; Lin AH; Prasad SC; Gotto AM; Gianturco SH
    J Biol Chem; 1984 Dec; 259(23):14728-35. PubMed ID: 6501314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
    Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D
    J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia.
    Ehnholm C; Mahley RW; Chappell DA; Weisgraber KH; Ludwig E; Witztum JL
    Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5566-70. PubMed ID: 6591204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of apolipoproteins C-II, C-III, and B in hypertriglyceridemic men. Changes after heparin-induced lipolysis.
    Huff MW; Breckenridge WC; Strong WL; Wolfe BM
    Arteriosclerosis; 1988; 8(5):471-9. PubMed ID: 3190554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of human intermediate and very low density lipoprotein subfractions from normal and dysbetalipoproteinemic plasma. In vivo studies in rat.
    Musliner TA; McVicker KM; Iosefa JF; Krauss RM
    Arteriosclerosis; 1987; 7(4):408-20. PubMed ID: 3606468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
    Zulewski H; Ninnis R; Miserez AR; Baumstark MW; Keller U
    J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.